Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Malolactomycin D, a potent inhibitor of transcription controlled by the Ras responsive element, inhibits Ras-mediated transformation activity with suppression of MMP-1 and MMP-9 in NIH3T3 cells

Oncogene volume 20, pages 6724–6730 (2001)Cite this article

Abstract

To search for anti-cancer agents, a screening system for Ras signal inhibitors was developed using a NIH3T3 cell line with an introduced reporter gene which is controlled by the Ras-responsive element (RRE). With this screening system, malolactomycin D was identified as a selective inhibitor of transcription from the RRE. This compound was found to preferentially inhibit the anchorage-independent growth rather than the anchorage-dependent growth of Ras-transformed NIH3T3 cells. The expression of matrix metalloproteinases MMP-1 and MMP-9, which have RRE in their promoters, were reduced by treatment with malolactomycin D at the translational and transcriptional levels. Analysis of the activity of mitogen-activated protein (MAP) kinases, which play important roles in transduction of the Ras signal, showed that malolactomycin D inhibits the activation of p38 MAP kinase and Jun N-terminal-kinase (JNK) but not extracellular signal-regulated kinase 1 or 2 (ERK1 or 2). These findings suggest that by inhibiting the pathway that leads to the activation of p38 MAP kinase and JNK, malolactomycin D suppresses the expression of MMPs. Since MMPs play important roles in metastasis and maintenance of the microenvironment of tumor cells, both of which facilitate tumor growth, the inhibition of MMPs by malolactomycin D is believed to contribute to its ability to inhibit Ras-mediated tumorigenesis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Aho S, Rouda S, Kennedy SH, Qin H, Tan EM . 1997 Eur. J. Biochem. 247: 503–510

  • Behre G, Smith LT, Tenen DG . 1999 BioTechniques 26: 24–28

  • Bortner DM, Langer SJ, Ostrowski MC . 1993 Crit. Rev. Oncog. 4: 137–160

  • Bos JL . 1989 Cancer Res. 49: 4682–4689

  • Brauchle M, Gluck D, Di Podova F, Han J, Gram H . 2000 Exp. Cell. Res. 258: 135–144

  • Burke LJ, Baniahmad A . 2000 FASEB J. 14: 1876–1888

  • Buttice G. Duterque-Coquillaud M, Basuyaux JP, Carrere S, Kurkinen M, Stehelin D . 1996 Oncogene 13: 2297–2306

  • Chomczynski P, Sacchi N . 1987 Anal. Biochem. 162: 156–159

  • Corcoran ML, Hewitt RE, Kleiner Jr DE, Stetler-Stevenson WG . 1996 Enzyme Protein 49: 7–19

  • Corominas M, Sloan SR, Leon J, Kamino H, Newcomb EW, Pellicer A . 1991 Environ. Health Perspect. 93: 19–25

  • Curran S, Murray GI . 1999 J. Pathol. 189: 300–308

  • Futamura M, Monden Y, Okabe T, Fujita-Yoshigaki J, Yokoyama S, Nishimura S . 1995 Oncogene 10: 1119–1123

  • Gardner AM, Vaillancourt RR, Johnson GL . 1993 J. Biol. Chem. 268: 17896–17901

  • Goustin AS, Leof EB, Shipley GD, Moses HL . 1986 Cancer Res. 46: 1015–1029

  • Gum R, Lengyel E, Juarez J, Chen JH, Sato H, Seiki M, Boyd D . 1996 J. Biol. Chem. 271: 10672–10680

  • Heussen C, Dowdle EB . 1980 Anal. Biochem. 102: 196–202

  • Himelstein BP, Lee EJ, Sato H, Seiki M, Muschel RJ . 1998 Clin. Exp. Metastasis 16: 169–177

  • Hodge C, Liao J, Stofega M, Guan K, Carter-Su C, Schwartz J . 1998 J. Biol. Chem. 273: 31327–31336

  • Imler JL, Schatz C, Wasylyk C, Chatton B, Wasylyk B . 1988 Nature 332: 275–278

  • Johansson N, Ala-aho R, Uitto V, Grenman R, Fusenig NE, Lopez-Otin C, Kahari VM . 2000 J. Cell. Sci. 113: 227–235

  • Kleiner DE, Stetler-Stevenson WG . 1999 Cancer Chemother. Pharmacol. 43: S42–S51

  • Kuo MH, Allis CD . 1998 BioEssays 20: 615–626

  • Newberry EP, Willis D, Latifi T, Boudreaux JM, Towler DA . 1997 Mol. Endocrinol. 11: 1129–1144

  • Newbold RF, Overell RW . 1983 Nature 304: 648–651

  • Nishimura S, Sekiya T . 1987 Biochem. J. 243: 313–327

  • Price MA, Hill C, Treisman R . 1996 Philos. Trans. R. Soc. Lond. B. Biol. Sci. 351: 551–559

  • Qin H, Sun Y, Benveniste EN . 1999 J. Biol. Chem. 274: 29130–29137

  • Reddy MA, Langer SJ, Colman MS, Ostrowski MC . 1992 Mol. Endocrinol. 6: 1051–1060

  • Rowinsky EK, Windle JJ, Von Hoff DD . 1999 J. Clin. Oncol. 17: 3631–3652

  • Simon C, Geopfert H, Boyd D . 1998 Cancer Res. 58: 1135–1139

  • Soga S, Kozawa T, Narumi H, Akinaga S, Irie K, Matsumoto K, Sharma SV, Nakano H, Mizukami T, Hara M . 1998 J. Biol. Chem. 273: 822–828

  • Spencer JA, Major ML, Misra RP . 1999 Mol. Cell Biol. 19: 3977–3988

  • Tanaka Y, Yoshida H, Enomoto Y, Shiomi K, Shinose M, Takahashi Y, Liu JR, Omura S . 1997 J. Antibiot. (Tokyo) 50: 194–200

  • Van Aelst L, Barr M, Marcus S, Polverino A, Wigler M . 1993 Proc. Natl. Acad. Sci. USA 90: 6213–6217

  • Watabe T, Yoshida K, Shindoh M, Kaya M, Fujikawa K, Sato H, Seiki M, Ishii S, Fujinaga K . 1998 Int. J. Cancer 77: 128–137

  • Westermarck J, Kahari VM . 1999 FASEB J. 13: 781–792

  • White LA, Maute C, Brinckerhoff CE . 1997 Connect. Tissue Res. 36: 321–335

  • Winitz S, Russell M, Qian NX, Gardner A, Dwyer L, Johnson GL . 1993 J. Biol. Chem. 268: 19196–19199

  • Zhao A, Lee SH, Mojena M, Jenkins RG, Patrick DR, Huber HE, Goetz MA, Hensens OD, Zink DL, Vilella D, Dombrowski AW, Lingham RB, Huang L . 1999 J. Antibiot. (Tokyo) 52: 1086–1094

Download references

Author information

Authors and Affiliations

  1. Banyu Tsukuba Research Institute in collaboration with Merck Research Laboratories, Okubo 3, 300-2611, Tsukuba, Japan

    Mayumi Futamura, Seigo Kamiya, Masao Tsukamoto, Atsushi Hirano, Yoshiaki Monden, Hiroharu Arakawa & Susumu Nishimura

Authors
  1. Mayumi Futamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seigo Kamiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masao Tsukamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Atsushi Hirano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshiaki Monden
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiroharu Arakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Susumu Nishimura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susumu Nishimura.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Futamura, M., Kamiya, S., Tsukamoto, M. et al. Malolactomycin D, a potent inhibitor of transcription controlled by the Ras responsive element, inhibits Ras-mediated transformation activity with suppression of MMP-1 and MMP-9 in NIH3T3 cells. Oncogene 20, 6724–6730 (2001). https://doi.org/10.1038/sj.onc.1204878

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204878

Keywords

This article is cited by

Search

Advanced search

Quick links